Fosigotifator

DB19409InvestigationalSmall molecule

Fosigotifator is under investigation in clinical trial NCT05757141 (An Open-label Exploratory Study of ABBV-CLS-7262 Subjects With Vanishing White Matter Disease).

Mechanism: Pharmacologically active on Translation initiation factor eIF2B subunit epsilon
Curator reviewed
Formula / weight: C₂₅H₂₇Cl₂F₂N₂O₉P · 639.37 g/mol (avg)
Also known as: Sodium ({(2S)-1,4-bis[2-(4-chloro-3- fluorophenoxy)acetamido]bicyclo[2.2.2]octan-2- yl}oxy)methyl hydrogen phosphate - 2-amino-2- (hydroxymethyl)propane-1,3-diol (1/1/1)
Code names: ABBV-CLS-7262 · CS-0716568 · DA-63590 · HY-153399

Resolves to

Compound

UNII3FQ7XKK8AYCAS2415715-84-1ChEMBLCHEMBL5315045ChEBI759733PubChem153563259

Structure

InChIKeyIURMHIZNAHLQRX-ANYOXOOPSA-NSMILESOP(O)(=O)OCO[C@H]1CC2(CCC1(CC2)NC(=O)COC1=CC=C(Cl)C(F)=C1)NC(=O)COC1=CC=C(Cl)C(F)=C1

Targets

Q13144EIF2B5

What you can answer from here — as of September 25, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Fosigotifator, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account